Quest Diagnostics Inc (DGX)
合理估值基本面
73
价格
$231.91
市值
$26.23B
第一部分 · 这家公司值多少
概览
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Labcorp is the other national US clinical laboratory network, selling the same routine and specialty test menu to the same physicians, hospitals, health plans and employers, and competing directly for the same managed-care contracts and hospital outreach deals.
Through Sonic Healthcare USA it runs a large network of regional clinical laboratories serving American physicians and hospitals, the same customers Quest bids for, and it is also Quest's main rival in Canada after the LifeLabs acquisition.
As one of the largest US reference laboratories, it takes in specialty and esoteric testing sent out by hospitals and physician practices across the country, the higher-value volume Quest's advanced diagnostics business targets.
A non-profit national reference laboratory owned by the University of Utah that competes for the same hospital and health-system send-out testing contracts Quest pursues with its hospital lab services.
It sells oncology and molecular testing to US pathologists, oncologists and hospitals, overlapping with the cancer and genetic testing line Quest is expanding within its advanced diagnostics.
Its clinical diagnostics division runs routine and specialty testing laboratories, including in the United States, competing for the same physician and hospital testing volumes as Quest.
资产负债表与流动性
营收
$11.56B
最近12个月（截至2026/6/30）
净利润
$1.06B
最近12个月（截至2026/6/30）
自由现金流
$1.36B
股东权益合计
$7.17B
负债合计
$9.02B
流动比率
1.59
利息覆盖率
6.37
债务/EBITDA
3.00
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$222.23
当前价格
$231.91
安全边际
-4.4%
公允价值区间
$155.33 - $289.13
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
24.74
ROE
13.8%
市净率（P/B）
3.42
P/FCF
19.07
毛利率
33.1%
ROIC
8.5%
盈利能力雷达图
价值创造（经济护城河）
ROIC
8.5%
WACC
7.1%
ROIC − WACC
+1.4 pp
ROIC 超过资本成本：公司正在为股东创造价值。
基本面分析标准
通过（20）
- EPS shows upward trend
- EPS CAGR 9.39%
- Price CAGR 9.85%
- ROIC 8.5%
- Gross Margin 33.1%
- P/FCF 19.07
- Debt/Equity ratio
- Operating Margin 14.1%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 14.5%
- Analyst Consensus 57% Buy
- Earnings Surprise avg 4.8%
- Earnings Quality (OCF/NI) 1.79
- Share Dilution 0.1%
- Net Margin Trend 9.2% vs 9.0%
- Piotroski F-Score 8/9
未通过（6）
- P/B Ratio 3.42
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 3.2%
不可用（2）
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-评分
财务状况强健
盈利质量
高质量：盈利有现金流支撑
股权稀释
股份数量稳定
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. James E. Davis | Chairman, CEO & President | 62 |
| Mr. Sam A. Samad | Executive VP & CFO | 55 |
| Mr. Michael E. Prevoznik J.D. | Senior VP & General Counsel | 63 |
| Ms. Catherine T. Doherty | Executive Vice President of Regional Businesses | 62 |
| Mr. Karthik Kuppusamy Ph.D. | Senior Vice President of Clinical Solutions | 55 |
| Mr. Michael J. Deppe | Senior VP, Corporate Controller & Chief Accounting Officer | 58 |
| Mr. Murali Balakumar | Senior VP and Chief Information & Digital Officer | - |
| Ms. Damini Chokshi | Vice President of Investor Relations | - |
| Ms. Kristin Lee Wallace Esq. | Senior VP & Chief Compliance Officer | - |
| Mr. Garry Clark | Senior VP and Chief Marketing & Communications Officer | - |
审计风险
6
董事会风险
7
薪酬风险
2
股东权利风险
2
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for DGX, sourced from Markets Gazette.